… We were interested in the results of a single dose study in liver transplant recipients in which
… We chose to study this lower dose of VGCV (450 mg daily) in kidney transplant recipients to …

… is sufficient, valganciclovir may be reduced to a 450-mg dose to … of low-dose valganciclovir
vs the standard dose in prophylaxis … -induced side effects in kidney transplantation recipients. …

… Before May 2011, standard CMV prophylaxis among CMV D+/R− kidney transplant
recipients at our institution consisted of 6 months of VGCV at a target dose of 900 mg daily (SD), …

… of CMV disease in renal transplant recipients. This is an … -dose valganciclovir prophylaxis
in renal transplant recipients. Despite a low daily dose, there was a high rate (20%) of dosage …

… risk kidney transplant recipients, with … kidney transplant recipients for efficacy and safety of
CMV chemo prophylaxis with low-dose (450 mg/d) versus highdose (900 mg/d) valganciclovir …

… in CMV serology naïve kidney transplant patients of CMV serology … -dose valganciclovir
(VGCV) prophylaxis, risk factors for late-onset CMV disease and its impact on kidney transplant …

… dosage of two 450 mg tablets once a day with doses to be taken within 30 min of breakfast.
… of valganciclovir CMV prophylaxis from 100 days to 200 days in kidney transplant patients at …

… Prophylaxis is widely used in renal transplant recipients (RTR) and has been associated
with reduced CMV disease, mortality, and graft rejection in high-risk individuals. Consensus …

… /recipient-positive (D+/R+) population is the largest proportion of renal transplant recipients
(… -risk D+/R+ population include prophylaxis with valganciclovir (VGCV) 900 mg/day for 3 …

… on chronic therapy, while they receive multiple doses of VGCV over a period of … patients
with a single dose of 900 mg of VGCV. Application of this study to the kidney transplant patients …